Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details
Prestin as a Biomarker for Hearing Loss in Cisplatin Therapy
Clinical Trial ( IRB ) #: 20-230-2
Title: Prestin as a Biomarker for Hearing Loss in Cisplatin Therapy
Principal Investigator: Dr. Kourosh Parham
Description: Cisplatin is a widely used and effective chemotherapeutic agent but well-known for also causing hearing loss or ototoxicity. However, there is currently no available blood-based biomarker test to evaluate the onset of ototoxicity in patients undergoing cisplatin. Diagnostic blood tests are easy to obtain and non-invasive and can provide critical information for treatment, intervention, and even prevention of downstream pathology. Several animal studies have shown outer hair cell electromotility protein prestin to be a promising biomarker for ototoxicity, however it has yet to be applied in human studies. Our hypothesis is that prestin may present as a measurable and specific serological biomarker for early detection of ototoxicity secondary to cisplatin chemotherapy. Our specific aim is to determine a temporal relationship between prestin levels and cisplatin treatment.
Classification:
  Cancer - General
  Ear, Nose and Throat
  Taste/Smell/Hearing
Eligibility Criteria: Check with study contact
How to Contact: Ruby Feng. Telephone: Not Available. Email: rfeng@uchc.edu
Enrollment Status/Comments: Enrolling/recruiting. For current recruitment status, please check with study contact.